Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "osteoarthritis"

39 News Found

ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules
Drug Approval | December 04, 2025

ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules

Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)


Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
Drug Approval | May 01, 2025

Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules

Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base


Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg
Drug Approval | February 22, 2025

Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg

Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis


Sun Pharma and Moebius Medical present Phase 2b study on MM-II
Clinical Trials | June 15, 2024

Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis


Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation
Drug Approval | August 03, 2023

Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation

Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.


Robotic surgery enhances success rate in knee replacements
Healthcare | July 26, 2023

Robotic surgery enhances success rate in knee replacements

Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%


Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction
News | June 28, 2023

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program


Zydus receives final approval from the USFDA for Diclofenac Sodium and Misoprostol Delayed Release Tablets
Drug Approval | June 14, 2023

Zydus receives final approval from the USFDA for Diclofenac Sodium and Misoprostol Delayed Release Tablets

Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States


‘SMART’ program for Ayurveda professionals to boost research in Ayurveda
Policy | January 03, 2023

‘SMART’ program for Ayurveda professionals to boost research in Ayurveda

The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research